# SLC18A1

## Overview
The SLC18A1 gene encodes the vesicular monoamine transporter 1 (VMAT1), a critical protein involved in the transport of monoamines such as dopamine, serotonin, and norepinephrine into synaptic vesicles. VMAT1 is an integral membrane protein characterized by 12 transmembrane domains, which facilitate its role in vesicular transport and neurotransmitter storage (Wimalasena2011Vesicular; Lawal2013SLC18:). This protein is essential for maintaining monoamine homeostasis, impacting various physiological processes and potentially influencing neuropsychiatric conditions such as Parkinson's disease, schizophrenia, and bipolar disorder (Eiden2004The; Lohoff2019Deletion). VMAT1's function is achieved through a proton antiport mechanism, exchanging protons for monoamines across the vesicular membrane, which is crucial for effective synaptic transmission and overall nervous system function (Eiden2004The). The gene's clinical significance is underscored by its association with neuropsychiatric disorders, where variations in SLC18A1 have been linked to altered neurotransmitter dynamics and related symptoms (Lohoff2019Deletion; Lohoff2006Variations).

## Structure
The SLC18A1 gene encodes the vesicular monoamine transporter 1 (VMAT1), a protein involved in the transport of monoamines into synaptic vesicles. VMAT1 is an integral membrane protein characterized by 12 transmembrane domains (TMDs), which facilitate its role in vesicular transport (Wimalasena2011Vesicular; Lawal2013SLC18:). The N- and C-termini of VMAT1 are located in the cytoplasmic phase of the vesicle, and the protein lacks a cleavable signal sequence (Wimalasena2011Vesicular). 

The protein structure includes a large glycosylated loop between the first and second transmembrane domains, which contains putative glycosylation sites (Wimalasena2011Vesicular). This loop is one of the most variable regions of the protein, contributing to its functional diversity. Specific motifs and aspartate residues within the transmembrane domains are critical for substrate recognition and transport (Eiden2004The). 

VMAT1 is an acidic glycoprotein with a molecular weight of approximately 70 kDa and shares high sequence homology with VMAT2, another member of the SLC18 family (Wimalasena2011Vesicular). The protein's structure and function are influenced by post-translational modifications, such as glycosylation, which may affect its activity and regulation.

## Function
The SLC18A1 gene encodes the vesicular monoamine transporter 1 (VMAT1), which is integral to the transport of monoamines such as dopamine, serotonin, and norepinephrine into synaptic vesicles within neurons and neuroendocrine cells. This transport process is essential for the regulated storage and release of neurotransmitters, which are critical for normal brain function and behavior (Eiden2004The; Lohoff2019Deletion). VMAT1 operates by exchanging protons for amines across the vesicular membrane, utilizing an electrochemical gradient established by proton pumping via a vacuolar ATPase. This allows for the accumulation of neurotransmitters in vesicles at a higher concentration than in the cytosol (Eiden2004The).

VMAT1 is expressed in neuroendocrine cells, including chromaffin and enterochromaffin cells, and plays a role in the storage of monoamines in secretory organelles (Erickson1996Distinct). The proper functioning of VMAT1 is crucial for neurotransmitter storage and release, impacting various physiological processes and potentially influencing conditions like Parkinson's, schizophrenia, and Alzheimer's disease (Eiden2004The). In healthy human cells, VMAT1 is vital for maintaining monoamine homeostasis, which is essential for mood regulation, cognition, and overall nervous system function (Lohoff2019Deletion).

## Clinical Significance
Mutations and alterations in the SLC18A1 gene, which encodes the vesicular monoamine transporter 1 (VMAT1), have been implicated in several neuropsychiatric disorders. Variations in this gene are associated with bipolar disorder (BPD) and schizophrenia (SZ). Specifically, the Thr136Ile polymorphism has been linked to BPD, with significant differences in allele frequencies observed between patients and controls (Lohoff2006Variations). This polymorphism is located in a domain of the transporter that interacts with inhibitors and substrates, potentially affecting serotonin transport capacity (Abdullah2017Genetic).

The expression of VMAT1 in the brain, particularly in regions such as the substantia nigra, hippocampus, and frontal lobe, suggests its involvement in central nervous system physiology and its potential role in the symptoms of mania, psychosis, or depression seen in BPD (Lohoff2006Variations). Additionally, VMAT1 knockout mice exhibit altered dopamine signaling, which may contribute to psychiatric disorders associated with dopaminergic dysfunction, such as schizophrenia and depression (Lohoff2019Deletion). These findings underscore the clinical significance of SLC18A1 in the etiology of neuropsychiatric disorders.

## Interactions
SLC18A1, also known as vesicular monoamine transporter 1 (VMAT1), is involved in the transport of monoamines into synaptic vesicles. This protein interacts with other components of the vesicular transport machinery, such as synaptophysin and synaptobrevin, which are integral to the storage and release of neurotransmitters in neurons. These interactions facilitate the proper functioning of neurotransmitter storage and exocytosis, which are critical for effective synaptic transmission (Lohoff2019Deletion).

The interactions of VMAT1 are significant in the context of its role in neurotransmission. VMAT1 is responsible for the vesicular accumulation of monoamines, a process that is essential for regulated exocytotic secretion. This function is achieved through a proton antiport mechanism, where VMAT1 exchanges protons for monoamines across the vesicular membrane (Eiden2004The). The structural configuration of VMAT1, characterized by multiple transmembrane domains, supports these interactions and the transport process (Eiden2004The).

The deletion of the VMAT1 gene in experimental models has shown that its absence leads to altered dopaminergic signaling, particularly in the frontal cortex, highlighting the importance of its interactions in maintaining normal neurotransmitter levels and signaling pathways (Lohoff2019Deletion).


## References


[1. (Eiden2004The) Lee E. Eiden, Martin K.-H. Sch�fer, Eberhard Weihe, and Burkhard Sch�tz. The vesicular amine transporter family (slc18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pfl�gers Archiv European Journal of Physiology, 447(5):636–640, February 2004. URL: http://dx.doi.org/10.1007/s00424-003-1100-5, doi:10.1007/s00424-003-1100-5. This article has 284 citations.](https://doi.org/10.1007/s00424-003-1100-5)

[2. (Wimalasena2011Vesicular) Kandatege Wimalasena. Vesicular monoamine transporters: structure‐function, pharmacology, and medicinal chemistry. Medicinal Research Reviews, 31(4):483–519, June 2011. URL: http://dx.doi.org/10.1002/med.20187, doi:10.1002/med.20187. This article has 144 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/med.20187)

[3. (Erickson1996Distinct) J D Erickson, M K Schafer, T I Bonner, L E Eiden, and E Weihe. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proceedings of the National Academy of Sciences, 93(10):5166–5171, May 1996. URL: http://dx.doi.org/10.1073/pnas.93.10.5166, doi:10.1073/pnas.93.10.5166. This article has 347 citations.](https://doi.org/10.1073/pnas.93.10.5166)

[4. (Lohoff2019Deletion) Falk W. Lohoff, Gregory V. Carr, Bethany Brookshire, Thomas N. Ferraro, and Irwin Lucki. Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling. Brain Research, 1712:151–157, June 2019. URL: http://dx.doi.org/10.1016/j.brainres.2019.01.029, doi:10.1016/j.brainres.2019.01.029. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.brainres.2019.01.029)

[5. (Abdullah2017Genetic) Al Mutery Abdullah, Kamal Walaa, Abduljalil Hussein Al Bloushi Hawraa, Sebastian Manjuran Mary, and Rais Naushad. Genetic polymorphism of vesicular monoamine transporter 1 gene (slc18a1) in emirati population. International Journal of Genetics and Molecular Biology, 9(3):16–20, May 2017. URL: http://dx.doi.org/10.5897/ijgmb2016.0136, doi:10.5897/ijgmb2016.0136. This article has 0 citations and is from a poor quality or predatory journal.](https://doi.org/10.5897/ijgmb2016.0136)

[6. (Lawal2013SLC18:) Hakeem O. Lawal and David E. Krantz. Slc18: vesicular neurotransmitter transporters for monoamines and acetylcholine. Molecular Aspects of Medicine, 34(2–3):360–372, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.005, doi:10.1016/j.mam.2012.07.005. This article has 110 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.005)

[7. (Lohoff2006Variations) Falk W Lohoff, John P Dahl, Thomas N Ferraro, Steven E Arnold, Jürgen Gallinat, Thomas Sander, and Wade H Berrettini. Variations in the vesicular monoamine transporter 1 gene (vmat1/slc18a1) are associated with bipolar i disorder. Neuropsychopharmacology, 31(12):2739–2747, August 2006. URL: http://dx.doi.org/10.1038/sj.npp.1301196, doi:10.1038/sj.npp.1301196. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/sj.npp.1301196)